Stock Track | Hims & Hers Soars to Record High on Raised Forecasts and Weight Loss Drug Plans

Stock Track

Nov 12, 2024

Shares of Hims & Hers Health Inc. (HIMS) surged to a record high on Friday, soaring 26.35% as investors cheered the company's raised revenue forecast and plans to capitalize on the booming weight loss drug market.

The telehealth firm, which provides access to prescription medications and other health products, raised its full-year revenue guidance to $1.46-$1.47 billion from $1.37-$1.40 billion last week. This upward revision came as HIMS announced it will add a generic version of Novo Nordisk's popular diabetes and weight loss drug liraglutide to its platform in 2025.

With demand for weight loss drugs skyrocketing and leading to shortages, HIMS is well-positioned to benefit from its ability to produce generic alternatives under U.S. regulations. The company's move to enter this lucrative market has investors bullish on its growth prospects, driving shares up 213% year-to-date, significantly outperforming the broader market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1180036669"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1180036669\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1180036669?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-12 01:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1180036669","market":"hk","top_or_hot":-1,"title":"Stock Track | Hims & Hers Soars to Record High on Raised Forecasts and Weight Loss Drug Plans","media":"Stock Track","content":"<p>Shares of Hims & Hers Health Inc. (HIMS) surged to a record high on Friday, soaring 26.35% as investors cheered the company's raised revenue forecast and plans to capitalize on the booming weight loss drug market.</p>\n\n<p>The telehealth firm, which provides access to prescription medications and other health products, raised its full-year revenue guidance to $1.46-$1.47 billion from $1.37-$1.40 billion last week. This upward revision came as HIMS announced it will add a generic version of Novo Nordisk's popular diabetes and weight loss drug liraglutide to its platform in 2025.</p>\n\n<p>With demand for weight loss drugs skyrocketing and leading to shortages, HIMS is well-positioned to benefit from its ability to produce generic alternatives under U.S. regulations. The company's move to enter this lucrative market has investors bullish on its growth prospects, driving shares up 213% year-to-date, significantly outperforming the broader market.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Soars to Record High on Raised Forecasts and Weight Loss Drug Plans</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Soars to Record High on Raised Forecasts and Weight Loss Drug Plans\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-12 01:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Hims & Hers Health Inc. (HIMS) surged to a record high on Friday, soaring 26.35% as investors cheered the company's raised revenue forecast and plans to capitalize on the booming weight loss drug market.</p>\n\n<p>The telehealth firm, which provides access to prescription medications and other health products, raised its full-year revenue guidance to $1.46-$1.47 billion from $1.37-$1.40 billion last week. This upward revision came as HIMS announced it will add a generic version of Novo Nordisk's popular diabetes and weight loss drug liraglutide to its platform in 2025.</p>\n\n<p>With demand for weight loss drugs skyrocketing and leading to shortages, HIMS is well-positioned to benefit from its ability to produce generic alternatives under U.S. regulations. The company's move to enter this lucrative market has investors bullish on its growth prospects, driving shares up 213% year-to-date, significantly outperforming the broader market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1180036669","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1180036669","pubTimestamp":1731347102,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Hims & Hers Health Inc.  surged to a record high on Friday, soaring 26.35% as investors cheered the company's raised revenue forecast and plans to capitalize on the booming weight loss drug market.The telehealth firm, which provides access to prescription medications and other health products, raised its full-year revenue guidance to $1.46-$1.47 billion from $1.37-$1.40 billion last week. This upward revision came as HIMS announced it will add a generic version of Novo Nordisk's popula","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"股票轨迹Hims&Hers因预测上调和减肥药计划而飙升至历史新高","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Shares of Hims & Hers Health Inc. (HIMS) surged to a record high on Friday, soaring 26.35% as investors cheered the company's raised revenue forecast and plans to capitalize on the booming weight loss drug market.\nThe telehealth firm, which provides access to prescription medications and other health products, raised its full-year revenue guidance to $1.46-$1.47 billion from $1.37-$1.40 billion last week. This upward revision came as HIMS announced it will add a generic version of Novo Nordisk's popular diabetes and weight loss drug liraglutide to its platform in 2025.\nWith demand for weight loss drugs skyrocketing and leading to shortages, HIMS is well-positioned to benefit from its ability to produce generic alternatives under U.S. regulations. The company's move to enter this lucrative market has investors bullish on its growth prospects, driving shares up 213% year-to-date, significantly outperforming the broader market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}